Integrating molecular diagnostics into anticancer drug discovery

被引：0

作者：

István Peták

Richárd Schwab

László Őrfi

László Kopper

György Kéri

机构：

[1] István Peták is at KPS Medical Biotechnology and Healthcare Services Ltd,and the Ist Department of Pathology and Experimental Cancer Research

[2] 5 Ribary,and the Department of Pharmaceutical Chemistry

[3] 1022 Budapest,László Kopper is at the Ist Department of Pathology and Experimental Cancer Research

[4] Hungary,Department of Medical Chemistry and Pathobiochemistry

[5] Semmelweis University,undefined

[6] 26 Üllői út,undefined

[7] 1085 Budapest,undefined

[8] Hungary.,undefined

[9] Richárd Schwab is at KPS Medical Biotechnology and Healthcare Services Ltd,undefined

[10] 5 Ribary,undefined

[11] 1022 Budapest,undefined

[12] Hungary.,undefined

[13] László Őrfi is at Vichem Chemie Research Ltd,undefined

[14] Budapest,undefined

[15] Hungary,undefined

[16] Semmelweis University,undefined

[17] Högyes E. u. 9.,undefined

[18] 1092 Budapest,undefined

[19] Hungary.,undefined

[20] Semmelweis University,undefined

[21] 26 Üllői út,undefined

[22] 1085 Budapest,undefined

[23] Hungary.,undefined

[24] György Kéri is at Vichem Chemie Research Ltd,undefined

[25] Budapest,undefined

[26] Hungary,undefined

[27] and the Pathobiochemistry Research Group of the Hungarian Academy of Sciences,undefined

[28] Semmelweis University,undefined

[29] Budapest,undefined

[30] H-1085,undefined

[31] Hungary.,undefined

来源：

Nature Reviews Drug Discovery | 2010年 / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Efforts to repeat the success of pioneering molecularly targeted cancer drugs, such as trastuzumab, for particular patient populations have been hampered by factors such as a lack of correlation between the molecular markers used to select patients for treatment and the drug response. This article highlights lessons learned from the development of drugs targeting members of the epidermal growth factor receptor family, and discusses strategies to decrease the risk of failure in clinical trials by more effectively integrating molecular diagnostics into anticancer drug discovery and development.

引用

页码：523 / 535

页数：12

共 50 条

[41] Anticancer drug discovery using chemical genomics
Sehgal, A
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (09) : 749 - 755
[42] Anticancer drug discovery and development throughout the world
Schwartsmann, G
Ratain, MJ
Cragg, GM
Wong, JE
Saijo, N
Parkinson, DR
Fujiwara, Y
Pazdur, R
Newman, DJ
Dagher, R
Di Leone, L
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 47S - 59S
[43] Gallnuts: A Potential Treasure in Anticancer Drug Discovery
Gao, Jiayu
Yang, Xiao
Yin, Weiping
Li, Ming
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 2018
[44] Crossroads of telomere biology and anticancer drug discovery
Seimiya, Hiroyuki
CANCER SCIENCE, 2020, 111 (09) : 3089 - 3099
[45] ANTICANCER DRUG DISCOVERY BASED ON PLANT BIODIVERSITY
Zhang, Hongjie
Liu, Kanglun
Guan, Yifu
ANTICANCER RESEARCH, 2014, 34 (10) : 6253 - 6254
[46] Soil DNA libraries for anticancer drug discovery
Robin K. Pettit
Cancer Chemotherapy and Pharmacology, 2004, 54 : 1 - 6
[47] Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen
Parr, AL
Myers, TG
Holbeck, SL
Loh, YLJ
Allegra, CJ
ANTI-CANCER DRUGS, 2001, 12 (07) : 569 - 574
[48] Cell cycle regulation and anticancer drug discovery
Bai, Jingwen
Li, Yaochen
Zhang, Guojun
CANCER BIOLOGY & MEDICINE, 2017, 14 (04) : 348 - 362
[49] Soil DNA libraries for anticancer drug discovery
Pettit, RK
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) : 1 - 6
[50] Cell cycle regulation and anticancer drug discovery
Jingwen Bai
Yaochen Li
Guojun Zhang
Cancer Biology & Medicine, 2017, (04) : 348 - 362

← 1 2 3 4 5 →